4 Healthcare Stock Stories Prescribed for Investors

Rosetta Genomics (NASDAQ:ROSG): Current price $4.48

Rosetta said that a manuscript in connection with the development and validation of its microRNA-based diagnostic assay for the classification of renal cell tumors has been accepted for publication by Molecular Oncology. Lead authors on the manuscript are Yael Spector, a scientist from Rosetta Genomics, and Dr. Eddie Fridman, a pathologist and an expert in urological pathology from the Isreali Sheba Medical Center in Tel-Hashomer. The company is a top developer and provider of microRNA-based molecular diagnostics.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

ROSG

Arena Pharmaceuticals (NASDAQ:ARNA): Current price $8.01

On Monday, Arena reported that Eisai Laboratorios, a subsidiary of Eisai Inc., has submitted a marketing authorization application for Belviq (lorcaserin HCl) in Mexico with the Federal Commission for the Protection Against Sanitary Risk. The intended indication for the drug is as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients having an initial body mass index of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) along with of at least one weight-related comorbid condition. Calculated on the MAA submission, Arena will receive a milestone payment of $500,000 from Eisai.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

ARNA

Covidien (NYSE: COV): Current price $67.71

The worldwide supplier of healthcare products announced Monday that it has won a patent infringement lawsuit against Ethicon Endo-Surgery, a Johnson & Johnson company, connected with Ethicon’s Harmonic line of ultrasonic surgical products. A federal court awarded Covidien a $176.5-million verdict, ruling that a number of claims of Covidien’s patents were valid, enforceable, and infringed by Ethicon. The amount of the verdict may be appealed, but it was based on an 8-percent royalty rate on infringing sales through March 2012, along with prejudgment interest.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

COV

Pfizer (NYSE:PFE): Current price $28.80

Pfizer, Procter & Gamble, and Arm & Hammer owner Church & Dwight Co. all bought manufacturers of dietary supplements in 2012, and more such deals are expected, as companies gamble that baby boomers and soaring healthcare costs will drive demand for products, according to the Wall Street Journal.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

PFE

Don’t Miss: Will This Court Decision Be a Thorn in the Side of Novartis?

More Articles About:   ,  

More from The Cheat Sheet